MEDP Stock Analysis — Medpace Holdings
Sector: Healthcare
AI Verdict
You’re paying a slight premium to the sector for Medpace’s growth and switching-cost moat, but the numbers say it’s expensive for the growth you’re getting unless that 24.2% revenue momentum keeps up.
Competitive Moat
Medpace provides contract clinical research services with deep regulatory expertise and integrated lab capabilities, making it a preferred partner for complex drug development. Its full-service model and long-term client relationships create switching costs that protect margins against smaller CRO competitors.
Summary
Medpace stands out for its double-digit forward EPS growth and a defensible niche in outsourced clinical trials.
Where It Stands
MEDP trades at 23.9x next year's earnings versus a healthcare sector median of 22x, with analysts expecting 10.3% EPS growth and trailing revenue up 24.2% year-over-year.
Key Metrics
- Trailing P/E: 26.4x
- Forward P/E: 23.9x
- PEG Ratio: 2.56
- Earnings Growth: +0.1%
- Revenue Growth: +0.2%
- 52-Week High: $628.92
- 52-Week Low: $284.48
Analyst Consensus
9 Buy · 10 Hold · 1 Sell (20 analysts)
Bull Case
Forward P/E of 23.9x for 10.3% expected EPS growth is a reasonable price if Medpace sustains its 24.2% revenue growth pace.
Bear Case
With a trailing PEG of 2.56, investors are paying up for growth that could disappoint if EPS momentum slows or sector multiples compress.
Catalyst to Watch
Watch for new large trial wins or regulatory changes that could accelerate or disrupt clinical outsourcing demand.